The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

Phase 4

Recruiting

• Conditions: 10033949; 10029149; hyperparathyroidism; increased activity of the parathyroids

• Registration Number: NL-OMON31628
• Lead Sponsor: Sint Lucas Andreas Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 114

Inclusion Criteria

- Hemodialysis patient > 18 years
- Secondary hyperparathyoidism

Exclusion Criteria

- Severe hypercalcemia (Ca2+ > 2,65 mmol/L)
- Severe hepatic dysfunction
- Overdosage of digoxin
- Hypersensitivity to vitamine D or an overdosage of vitamin D
- Parathyroidectomy
- < 18 years
- Pregnancy
- Mental illness

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>.</p><br>